Pacific Biosciences Of California (PACB) Gains from Sales and Divestitures (2019 - 2022)

Pacific Biosciences Of California's Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $2.6 million for Q4 2022.

• In Q4 2022, Gains from Sales and Divestitures rose 43.6% year-over-year to $2.6 million; the TTM figure through Dec 2022 stood at $2.6 million (up 43.6% YoY), while the FY2022 annual figure was $2.6 million, up 43.6% from the prior year.
• Gains from Sales and Divestitures was $2.6 million for Q4 2022 at Pacific Biosciences Of California, up from $2.4 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $2.6 million in Q4 2022 to a low of $2026.0 in Q2 2022.
• Historically, Gains from Sales and Divestitures has averaged $1.1 million across 4 years, with a median of $876000.0 in 2020.
• The sharpest annual moves came in 2020 and 2022: Gains from Sales and Divestitures jumped 390.2% in 2020, then tumbled 99.86% in 2022.
• A 4-year view of Gains from Sales and Divestitures shows it stood at $204000.0 in 2019, then jumped by 390.2% to $1.0 million in 2020, then jumped by 79.8% to $1.8 million in 2021, then soared by 43.6% to $2.6 million in 2022.
• The last three Gains from Sales and Divestitures figures came in at $2.6 million (Q4 2022), $2.4 million (Q3 2022), and $2026.0 (Q2 2022), per Business Quant data.